NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00327678,Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults,https://clinicaltrials.gov/study/NCT00327678,,COMPLETED,"This study is a multicenter trial of treatment for young ALL patients. All ALL patients will receive the same steroid pre-phase in order to evaluate sensitivity or resistance. Then, patients will be included into 3 specific trials according to biological features (immunophenotype, cytogenetics, and molecular biology).

Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2005:

* T ALL or B ALL non Ph (N=810 patients planned).
* GRAALL 2005 R: B ALL non Ph CD20+ (N=220 patients planned).
* GRAAPH 2005: ALL Ph+ (N=270 patients planned)",NO,"Leukemia, Lymphocytic",DRUG: Rituximab|DRUG: Imatinib Mesylate,"Event free survival for all patients, January 2014|GRAAPH: Percentage of patients with minimum residual disease (MRD) < 10-4 after induction and/or consolidation (= salvage), January 2014","CR in 1 or 2 courses, January 2014|Death in induction, January 2014|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, January 2014|Death in first CR, January 2014|Relapse, January 2014|Relapse free survival, January 2014|Overall Survival, January 2014",,Assistance Publique - HÃ´pitaux de Paris,Group for Research in Adult Acute Lymphoblastic Leukemia,ALL,ADULT,PHASE3,1080,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GRAALL 2005,2006-05,2014-04,2014-04,2006-05-18,,2016-06-27,"Group for Research in Adult Acute Lymphoblastic Leukemia - GRAALL -, Lyon, 69, France",
